• Upstream Bio outlined Phase 3 plans for verekitug in severe asthma and CRSwNP, targeting a single 400 mg quarterly at-home injection.
• Phase 2 CRSwNP VIBRANT met its primary endpoint, with a -1.8 nasal polyp score treatment difference versus placebo (p<0.0001).
• VIBRANT also showed a -0.8 nasal congestion score difference (p=0.0003) and a 76% reduction in surgery or steroid need (p=0.03).
• Phase 2 severe asthma VALIANT reported a 56% reduction in annualized exacerbation rate (p<0.0003), with 122 mL FEV1 improvement.
• Enrollment completed in the Phase 2 COPD VENTURE trial, with data expected in H2 2027; existing capital expected to fund operations through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.